Taking place in Birmingham between 10th – 11th February, the event promises to be unmissable for any diagnostics regulatory affairs professional. Reflecting the event’s status as the leading UK diagnostics regulatory conference, MHRA Chief Executive Lawrence Tallon will deliver the closing keynote address.

On Monday 18th August, BIVDA chaired a meeting between Professor Sir Chris Whitty and his policy and delivery teams, and the BIVDA members who had been involved in an industry consensus statement entitled “Unlocking Our Communities Diagnostic Potential”. BIVDA’s report underlines the key opportunities to support the adoption of point-of-care testing in primary care and community care settings.

After last year’s record event, BIVDA’s 2026 Regulatory Affairs Seminar will be held on the 10th and 11th February in Birmingham. In a sign of the importance of this event, MHRA Chief Executive Lawrence Tallon will be closing the event with a keynote address.

BIVDA’s Director of Policy and Programmes Paul Fisher recently wrote a guest blog for the Health Innovation Network on the value of diagnostics. In his blog, he calls for a new, innovative approach to how the value of diagnostics are assessed by health systems.

In Vitro Diagnostics are a key part of any health system. Before being placed on the market, tests are checked by the Medicines and Healthcare products Regulatory Agency (MHRA) to ensure they are safe and legal. The laboratories which analyse these tests adhere to stringent quality assurance standards. Tests supplied by the NHS also go through a rigorous procurement process before being placed in the hands of medical professionals.

The Covid Test Device Approval (CTDA) was introduced during the pandemic as a measure to regulate an influx of new Covid-19 tests. Its retention post-Covid means any test on the UK market which tests for Covid – even as part of testing for other infections – still needs to pass an additional regulatory step unique to UK. This has kept products off the UK market and is costly and time-consuming.

On Friday 4th July, BIVDA hosted a webinar examining what the newly-released NHS 10-Year Plan means for the future of diagnostics, reaching an audience of 114 from our membership, the NHS and government.

A year after coming to power, the Government have released their plan for NHS reform.

London, United Kingdom, April 1st, 2025 – The British In Vitro Diagnostics Association (BIVDA), along with leading industry and health charities, today launched a new policy declaration that highlights the value of community diagnostics and their role in a future neighbourhood NHS.

BIVDA is excited to announce a new partnership with MedBoard, an innovative cloud platform that centralises global medical, MedTech, Digital Health, and Pharma information. MedBoard empowers professionals, teams, and organisations with accessible, cutting-edge digital tools to enhance their work and decision-making.